Texas Oncology - Bedford

The trials here

What the 18 trials at this site are about, from their registry records.

Conditions

• Lung cancer5 trials
• Ovarian cancer3 trials
• Triple-negative breast cancer2 trials
• Cervical cancer1 trial
• Endometrial cancer1 trial
• Gastric and oesophageal cancer1 trial
• Mantle cell lymphoma1 trial
• Melanoma1 trial
• Metastatic breast cancer1 trial
• Pancreatic cancer1 trial
• Prostate cancer1 trial

Phase

• Phase 314 trials
• Phase 23 trials
• Phase 2/31 trial

Status

• Active, not recruiting9 trials
• Completed4 trials
• Recruiting3 trials
• Terminated2 trials

Lead sponsor

• Daiichi Sankyo2 trials
• National Cancer Institute (NCI)2 trials
• Agenus Inc.1 trial
• Amgen1 trial
• Eikon Therapeutics1 trial
• and 11 more

Running trials

• Recruiting

  A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting

  NCT07022483· Phase 3· Daiichi Sankyo· Source

• Recruiting

  A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

  NCT06246916· Phase 3· Regeneron Pharmaceuticals· Source

  Contact: Clinical Trials Administrator

• Recruiting

  A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

  NCT06161025· Phase 2/3· Daiichi Sankyo· Source

• Active, not recruiting

  A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

  NCT06246110· Phase 2· Eikon Therapeutics· Source

• Recruiting

  A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

  NCT06038578· Phase 2· Toray Industries, Inc· Source

  Contact: Pre-Screener

• Active, not recruiting

  Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

  NCT05169567· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT05089734· Phase 3· Gilead Sciences· Source

• Active, not recruiting

  Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

  NCT04662255· Phase 3· Loxo Oncology, Inc.· Source

• Active, not recruiting

  A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

  NCT03522246· Phase 3· pharmaand GmbH· Source

• Active, not recruiting

  Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

  NCT03281954· Phase 3· NSABP Foundation Inc· Source

• Active, not recruiting

  Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT02446600· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967· Phase 3· NRG Oncology· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Endometrial cancer1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Melanoma1 recruiting

Closed trials

• Completed

  Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

  NCT04303780· Phase 3· Amgen· Source

• Terminated

  RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

  NCT03894215· Phase 2· Agenus Inc.· Source

• Completed

  M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

  NCT03631706· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Terminated

  Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

  NCT03520686· Phase 3· ImmunityBio, Inc.· Source

• Completed

  Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

  NCT01013649· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

  NCT00936390· Phase 3· Radiation Therapy Oncology Group· Source